- 57 min ago Omicron: Parliamentary Panel Recommends Evaluation Of Vaccines, More Research For Booster Dose
- 2 hrs ago Sleeping With Curly Hair: 7 Tips To Protect Your Mane!
- 3 hrs ago Katrina Kaif Looks Gorgeous In Pristine White Ruffled Saree As She Attends Her Pre-Wedding Function!
- 4 hrs ago COVID-19: Govt Writes To States/UT Over Rising Weekly Positivity Rates And Deaths
- Sports BBL 2021-22: Schedule, Dates, Venues, Time in IST, TV Channel List & Live Streaming Details in India
- Technology LinkedIn Now Supports Hindi Language; Here’s How To Switch To Hindi Language
- Movies Shefali Jariwala Reveals After 'Kaanta Laga' She Didn't Do Much Work As She Suffered From Epilepsy Seizures
- Finance Stocks To Buy: 5 Stocks From Nifty Trading At Up To 64% Discount
- News Ex Shia waqf board chief, Rizvi converts to Hinduism
- Education NIOS On Demand Examination 2022 Registration For Class 10, 12 Starts Today, Steps To Register For NIOS ODE
- Automobiles Cars Are About To Get Pricier In India From January 2022 Onwards
- Travel Budget Friendly Winter Places To Visit Around Dispur
Bharat Biotech, which completed the Phase 2/3 trials of Covid-19 vaccine Covaxin for use in children under 18 years of age, has submitted the data to the Central Drugs Standard Control Organisation for its verification and subsequent approval for Emergency Use Authorisation for the jab, company sources said on Wednesday.
"Covaxin clinical trial data of 2-18 years age group has been submitted to CDSCO. This is feasible due to the safety of the manufacturing platform and empirical evidence from Phase 1,2 and 3 clinical trials in adults," sources told PTI.
Chairman and Managing Director of Bharat Biotech International Ltd, Krishna Ella, had said on September 21 that the Paediatric Covaxin completed phase 2/3 trials with about 1,000 subjects and the data analysis was going on.
As part of the Phase II/III trial, the two-dose Covaxin was administered with 28 days apart.
"We will be submitting the data (to the regulator) by next week," he had said.
He also had said that Phase 2 trials of an intranasal vaccine to prevent Covid-19 were going on and expected to be over in October.
If approved, Covaxin will be the first Covid-19 vaccine that can be administered to children in India.